Amendment: SEC Form SC 13G/A filed by Invivyd Inc.

11/12/24 10:32:12 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $IVVD alert in real time by email

SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.5 INVIVYD INC COMMON STOCK Cusip #00534A102 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #00534A102 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 7,317,347 Item 6: 0 Item 7: 7,320,982 Item 8: 0 Item 9: 7,320,982 Item 11: 6.129% Item 12: HC Cusip #00534A102 Item 1: Reporting Person - Abigail P. Johnson Item 2: (a) [ ] (b) [ ] Item 4: United States of America Item 5: 0 Item 6: 0 Item 7: 7,320,982 Item 8: 0 Item 9: 7,320,982 Item 11: 6.129% Item 12: IN Item 1(a). Name of Issuer: INVIVYD INC Item 1(b). Address of Issuer's Principal Executive Offices: 1601 TRAPELO ROAD,, SUITE 178 WALTHAM, MA 02451 USA Item 2(a). Name of Person Filing: FMR LLC Item 2(b). Address or Principal Business Office or, if None, Residence: 245 Summer Street, Boston, Massachusetts 02210 Item 2(c). Citizenship: Not applicable Item 2(d). Title of Class of Securities: COMMON STOCK Item 2(e). CUSIP Number: 00534A102 Item 3. This statement is filed pursuant to Rule 13d-1(b) or 13d-2(b) or (c) and the person filing, FMR LLC, is a parent holding company in accordance with Section 240.13d-1(b)(1)(ii)(G). (Note: See Exhibit A). Item 4. Ownership (a) Amount Beneficially Owned: 7,320,982 (b) Percent of Class: 6.129% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page (ii) shared power to vote or to direct the vote: 0 (iii) sole power to dispose or to direct the disposition of: 7,320,982 (iv) shared power to dispose or to direct the disposition of: 0 Item 5. Ownership of Five Percent or Less of a Class. Not applicable. Item 6. Ownership of More than Five Percent on Behalf of Another Person. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of INVIVYD INC. No one other person's interest in the COMMON STOCK of INVIVYD INC is more than five percent of the total outstanding COMMON STOCK. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. See attached Exhibit A. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Signature After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. November 8, 2024 Date /s/ Stephanie J. Brown Signature Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. Exhibit A Pursuant to the instructions in Item 7 of Schedule 13G, the following table lists the identity and Item 3 classification, if applicable, of each relevant entity that beneficially owns shares of the security class being reported on this Schedule 13G. Entity ITEM 3 Classification Fidelity Management & Research Company LLC IA Fidelity Management Trust Company BK Abigail P. Johnson is a Director, the Chairman and the Chief Executive Officer of FMR LLC. Members of the Johnson family, including Abigail P. Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. This filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies (collectively, the "FMR Reporters"). This filing does not reflect securities, if any, beneficially owned by certain other companies whose beneficial ownership of securities is disaggregated from that of the FMR Reporters in accordance with Securities and Exchange Commission Release No. 34-39538 (January 12, 1998). RULE 13d-1(k)(1) AGREEMENT The undersigned persons, on November 8, 2024, agree and consent to the joint filing on their behalf of this Schedule 13G in connection with their beneficial ownership of the COMMON STOCK of INVIVYD INC at September 30, 2024. FMR LLC By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries* Abigail P. Johnson By /s/ Stephanie J. Brown Stephanie J. Brown Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson** * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Get the next $IVVD alert in real time by email

Recent Analyst Ratings for

$IVVD

Date	Price Target	Rating	Analyst
12/22/2025	$10.00	Buy	BTIG Research
11/25/2025		Buy → Hold	D. Boral Capital
10/6/2025	$10.00	Overweight	Cantor Fitzgerald
4/5/2024	$9.00	Neutral → Buy	Guggenheim
3/26/2024	$4.00 → $10.00	Equal-Weight → Overweight	Morgan Stanley
12/19/2023	$1.00 → $4.00	Underweight → Equal-Weight	Morgan Stanley
5/1/2023	$5.00	Buy	H.C. Wainwright

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Invivyd Inc.

11/12/24 10:32:12 AM ET

$IVVD

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Get the next $IVVD alert in real time by email

Recent Analyst Ratings for

$IVVD

Date	Price Target	Rating	Analyst
12/22/2025	$10.00	Buy	BTIG Research
11/25/2025		Buy → Hold	D. Boral Capital
10/6/2025	$10.00	Overweight	Cantor Fitzgerald
4/5/2024	$9.00	Neutral → Buy	Guggenheim
3/26/2024	$4.00 → $10.00	Equal-Weight → Overweight	Morgan Stanley
12/19/2023	$1.00 → $4.00	Underweight → Equal-Weight	Morgan Stanley
5/1/2023	$5.00	Buy	H.C. Wainwright

More analyst ratings

Amendment: SEC Form SC 13G/A filed by Invivyd Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$IVVD

Amendment: SEC Form SC 13G/A filed by Invivyd Inc.

Crush Q1 2026 with the Best AI Superconnector

Recent Analyst Ratings for
$IVVD

$IVVD
Analyst Ratings

BTIG Research initiated coverage on Invivyd with a new price target

Invivyd downgraded by D. Boral Capital

Cantor Fitzgerald initiated coverage on Invivyd with a new price target

$IVVD
Insider Trading

SEC Form 4 filed by Chief Financial Officer Duke William E.

SEC Form 4 filed by Chief Human Resources Officer Green Julie

SEC Form 4 filed by Chief Commercial Officer Lee Timothy Edward

$IVVD
Press Releases

Invivyd Aligns with the U.S. FDA on LIBERTY, a Phase 3 Trial to Evaluate the Safety of VYD2311 Antibody Versus mRNA COVID Vaccine, and to Characterize the Safety and Immunology of Antibody and Vaccine Co-Administration

Invivyd Announces Partnership with World Champion Skier Lindsey Vonn to Educate Americans on Antibodies and Disease Prevention

Invivyd and SPEAR Study Group Announce Plan for Phase 2 Study of VYD2311 for Treatment of Long COVID and COVID Vaccine-Injured Individuals to Commence Mid-2026

$IVVD
SEC Filings

Invivyd Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Other Events

Amendment: SEC Form SCHEDULE 13D/A filed by Invivyd Inc.

SEC Form EFFECT filed by Invivyd Inc.

$IVVD
Insider Purchases

Director Mclaughlin Kevin F bought $125,000 worth of shares (50,000 units at $2.50) (SEC Form 4)

$IVVD
Leadership Updates

Invivyd to Host Webcast on the REVOLUTION Clinical Program for VYD2311, a Vaccine-Alternative Antibody to Prevent COVID

Invivyd Appoints Paul B. Bolno, M.D. to Its Board of Directors

Invivyd Announces Appointment of Kristie Kuhl as Chief Communications Officer

$IVVD
Financials

Invivyd to Host Third Quarter 2025 Financial Results and Corporate Update Call on November 6, 2025

Invivyd Reports First Quarter 2025 Financial Results and Recent Business Highlights

Invivyd to Host First Quarter 2025 Financial Results and Corporate Update Conference Call on May 15, 2025

$IVVD
Large Ownership Changes

Amendment: SEC Form SC 13D/A filed by Invivyd Inc.